<DOC>
	<DOCNO>NCT00715364</DOCNO>
	<brief_summary>To assess safety tolerability NTx™-265 give acute ischemic stroke patient . To assess neurological outcome acute ischemic stroke patient treat NTx™-265 , compare patient give placebo control .</brief_summary>
	<brief_title>REGENESIS ( US ) : A Phase IIb Prospective , Randomized , Double-blind , Placebo Controlled Study NTx™-265 : Human Chorionic Gonadotropin ( hCG ) Epoetin Alfa ( EPO ) Acute Ischemic Stroke Patients</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Age 1885 . NIHSS score 624 within 2448 hour stroke onset enrolment . Stroke ischemic origin , supratentorial , radiologically confirm ( CT scan diagnostic MRI ) prior enrolment . Patient 2448 hour time stroke onset first dose NTx™265 therapy administer . Time onset symptoms begin ; stroke occur sleep , time onset patient last see selfreported normal . Reasonable expectation availability receive full 9 day NTx™265 course therapy , available subsequent followup visit . Reasonable expectation patient receive standard poststroke physical , occupational , speech , cognitive therapy indicate . Female patient either : 1. childbearing potential , defined postmenopausal least 1 year surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) , 2. childbearing potential , agree use two follow effective separate form contraception throughout study , include follow visit : ) condom , sponge , foam , jelly , diaphragm intrauterine device ( IUD ) contraceptive ( e.g . implant , injectables , combine oral , etc . ) OR ii ) vasectomize partner OR iii ) abstinence Patients present lacunar , hemorrhagic and/or brain stem stroke Patients classify comatose , defined patient require repeat stimulation attend , obtund require strong painful stimulation make movement ( NIHSS 1A score must &lt; 2 ) Women test positive pregnancy , breastfeeding , use highly effective method birth control maintain duration study Serum hemoglobin &gt; 16 g/dL ( male ) &gt; 14 g/dL ( female ) ; platelet count &gt; 400,000/mm3 Advanced liver , kidney , cardiac , pulmonary disease ; former operationally define use NCI Toxicity Criteria ( Grade 2 high ) Serum bilirubin &gt; 1.5 x ULN Alkaline phosphatase &gt; 2.5 x ULN AST ALT &gt; 2.5 x ULN Creatinine &gt; 2.0 x ULN Patients know document Transferrin saturation &lt; 20 % ferritin &lt; 100 ng/ml Patients know documented elevate PSA level Patients know history hypercoagulability , include know cardiolipin/antiphospholipid antibody syndrome Expected survival &lt; 1 year Allergy contraindication hCG Allergy contraindication epoetin alfa : A known diagnosis cancer ( except nonmalignant skin cancer ) Uncontrolled hypertension , define context acute stroke blood pressure persistently 220 mm Hg systolic 120 mm Hg diastolic despite antihypertensive therapy Use either hCG epoetin alfa within previous 90 day Any condition know elevate hCG , active prior 24 month , e.g. , choriocarcinoma germ cell tumor Patients prestroke/premorbid modify Rankin Score ( mRS ) ≥ 2 Any patient live nursing home supervise living center . Patients must historically fully independent activity daily live include banking , shopping , cooking , toileting , shower dress Any medical condition degree stroke , investigator 's opinion , patient include trial With exception qualify stroke , stroke within previous 3 month Patients take antiplatelet anticoagulant therapy Preexisting active major psychiatric chronic neurological disease Consume , average , great 14 alcoholic drink per week , history substance abuse dependency within 12 month prior study Currently participate another investigational study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>